275 related articles for article (PubMed ID: 10598192)
21. [Early therapeutic management of patients genetically predisposed to medullary thyroid cancer].
Murat A; Modigliani E; Conte-Devolx B; Rohmer V; Leclerc L; Guilhem I; Bigorgne JC; Boneu A; Maes B; Chabre O; Niccoli P; Schuffenecker I; Giraud S
Ann Chir; 1998; 52(5):455-60. PubMed ID: 9752487
[TBL] [Abstract][Full Text] [Related]
22. Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia.
Colombo-Benkmann M; Brämswig J; Höppner W; Gellner R; Hengst K; Böcker W; Senninger N
World J Surg; 2002 Oct; 26(10):1286-90. PubMed ID: 12205548
[TBL] [Abstract][Full Text] [Related]
23. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Machens A; Dralle H
J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
[TBL] [Abstract][Full Text] [Related]
24. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
[TBL] [Abstract][Full Text] [Related]
25. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.
Weber T; Schilling T; Frank-Raue K; Colombo-Benkmann M; Hinz U; Ziegler R; Klar E
Surgery; 2001 Dec; 130(6):1044-9. PubMed ID: 11742336
[TBL] [Abstract][Full Text] [Related]
26. Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery.
Schott M; Willenberg HS; Sagert C; Nguyen TB; Schinner S; Cohnen M; Cupisti K; Eisenberger CF; Knoefel WT; Scherbaum WA
Clin Endocrinol (Oxf); 2007 Mar; 66(3):405-9. PubMed ID: 17302876
[TBL] [Abstract][Full Text] [Related]
27. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal.
Faggiano A; Milone F; Ramundo V; Chiofalo MG; Ventre I; Giannattasio R; Severino R; Lombardi G; Colao A; Pezzullo L
J Clin Endocrinol Metab; 2010 Sep; 95(9):E32-6. PubMed ID: 20534767
[TBL] [Abstract][Full Text] [Related]
28. Ghrelin in human medullary thyroid carcinomas.
Morpurgo PS; Cappiello V; Verga U; Vicentini L; Vaghi I; Lauri E; Nebuloni M; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):437-41. PubMed ID: 16181236
[TBL] [Abstract][Full Text] [Related]
29. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
30. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin.
Scheuba C; Kaserer K; Kotzmann H; Bieglmayer C; Niederle B; Vierhapper H
Thyroid; 2000 May; 10(5):413-6. PubMed ID: 10884188
[TBL] [Abstract][Full Text] [Related]
32. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
[TBL] [Abstract][Full Text] [Related]
33. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.
Barbot N; Calmettes C; Schuffenecker I; Saint-André JP; Franc B; Rohmer V; Jallet P; Bigorgne JC
J Clin Endocrinol Metab; 1994 Jan; 78(1):114-20. PubMed ID: 7904611
[TBL] [Abstract][Full Text] [Related]
34. Routine measurement of plasma calcitonin in nodular thyroid diseases.
Vierhapper H; Raber W; Bieglmayer C; Kaserer K; Weinhäusl A; Niederle B
J Clin Endocrinol Metab; 1997 May; 82(5):1589-93. PubMed ID: 9141554
[TBL] [Abstract][Full Text] [Related]
35. Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin.
Lorenz K; Elwerr M; Machens A; Abuazab M; Holzhausen HJ; Dralle H
Langenbecks Arch Surg; 2013 Mar; 398(3):403-9. PubMed ID: 23408061
[TBL] [Abstract][Full Text] [Related]
36. Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia.
Borchhardt KA; Heinzl H; Gessl A; Hörl WH; Kaserer K; Sunder-Plassmann G
Kidney Int; 2006 Dec; 70(11):2014-20. PubMed ID: 17051143
[TBL] [Abstract][Full Text] [Related]
37. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
[TBL] [Abstract][Full Text] [Related]
38. [Total thyroidectomy in C-cell hyperplasia of the thyroid gland].
Stojanović D; Paunović I; Caparević Z; Lalosević D; Stojanović M
Med Pregl; 2003; 56(9-10):481-4. PubMed ID: 14740541
[TBL] [Abstract][Full Text] [Related]
39. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients.
Chambon G; Alovisetti C; Idoux-Louche C; Reynaud C; Rodier M; Guedj AM; Chapuis H; Lallemant JG; Lallemant B
J Clin Endocrinol Metab; 2011 Jan; 96(1):75-81. PubMed ID: 20881258
[TBL] [Abstract][Full Text] [Related]
40. Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test".
Niederle MB; Scheuba C; Gessl A; Li S; Koperek O; Bieglmayer C; Riss P; Selberherr A; Niederle B
Biochem Med (Zagreb); 2018 Oct; 28(3):030710. PubMed ID: 30429678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
